ABSTRACT
OBJECTIVES: Although interferon beta-1a (IFNß-1a), 1b (IFNß-1b), and fingolimod have been approved as multiple sclerosis (MS) treatments, they have not yet been included on the National List of Essential Medicines (NLEM) formulary in Thailand. This study aimed to evaluate the cost-utility of MS treatments compared with best supportive care (BSC) based on a societal perspective in Thailand. METHODS: A Markov model with cost and health outcomes over a lifetime horizon with a 1-month cycle length was conducted for relapsing-remitting MS (RRMS) patients. Cost and outcome data were obtained from published studies, collected from major MS clinics in Thailand and a discount rate of 3 percent was applied. The incremental cost-effectiveness ratio (ICER) was calculated and univariate and probabilistic sensitivity analyses were performed. RESULTS: When compared with BSC, the ICERs for patients with RRMS aged 35 years receiving fingolimod, IFNß-1b, and IFNß-1a were 33,000, 12,000, and 42,000 US dollars (USD) per quality-adjusted life-year (QALY) gained, respectively. At the Thai societal willingness to pay (WTP) threshold of USD 4,500 per QALY gained, BSC had the highest probability of being cost-effective (49 percent), whereas IFNß-1b and fingolimod treatments showed lower chance being cost-effective at 25 percent and 18 percent, respectively. CONCLUSIONS: Compared with fingolimod and interferon treatments, BSC remains to be the most cost-effective treatment for RRMS in Thailand based on a WTP threshold of USD 4,500 per QALY gained. The results do not support the inclusion of fingolimod or interferon in the NLEM for the treatment of RRMS unless their prices are decreased or special schema arranged.
ABSTRACT
BACKGROUND: Multiple sclerosis (MS) and neuromyelitis optica spectrum (NMOSD) cause several symptoms that negatively impact on patient's quality of life. No study has ever conducted to examine the quality of life of MS and NMOSD patients, especially in terms of health utility, among the non-western population. This study aims to examine health utility among MS and NMOSD patients in Thailand. METHODS: A multicenter cross-sectional study including 104 MS and 186 NMOSD patients was conducted. Health utility was measured using EQ-5D questionnaire. Demographic data, clinical data and Expanded Disability Status Scales (EDSS) were also collected. RESULTS: Health utility scores of MS or NMOSD were 0.41⯱â¯0.36 and 0.41⯱â¯0.32, respectively. No significant difference between MS and NMOSD in term of health utility score was found. Pain, mobility, and anxiety/depression are the three most affected domains among both MS and NMOSD patients. Age at onset less than 40 years and EDSS score less than or equal to 2.5 were significantly associated with higher health utility score in MS and NMOSD patients. CONCLUSION: Our findings clearly demonstrated the negative impact of MS and NMOSD on patients' health-related quality of life. Effective interventions that target pain, mobility, and anxiety/depression should be provided to improve quality of life of these patients. Health utility estimates from this study can be used as an important input for economic evaluations of treatments for MS and NMOSD to inform resource-allocation decisions.
